Cefiderocol ( DrugBank: Cefiderocol )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 299 | 嚢胞性線維症 | 1 |
299. 嚢胞性線維症
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05314764 (ClinicalTrials.gov) | June 1, 2022 | 29/3/2022 | Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis | Population Pharmacokinetics of Cefiderocol During Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis | Cystic Fibrosis;Pneumonia, Bacterial | Drug: Cefiderocol | Hartford Hospital | Shionogi Inc.;Keystone Bioanalytical, Inc.;Indiana University Health Methodist Hospital;University of Pittsburgh Medical Center;University of Texas | Recruiting | 18 Years | N/A | All | 12 | Phase 4 | United States |